{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65337aeb32aab9001268a81f/68396f15b2e4c2434beb02ed?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Efanesoctocog alfa for severe haemophilia A: expert perspective with Dr Susie Shapiro","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/65337aeb32aab9001268a81f/1748593940286-95572c7c-fb16-4437-b868-0cd09196eb78.jpeg?height=200","description":"<p>On this episode, Pip interviews Dr Susie Shapiro, consultant haematologist in Oxford, UK, about the recent UK approval of efanesoctocog alfa, a very long half-life factor VIII product for severe haemophilia. To find out more about this treatment, listen to our first episode on the subject (Efanesoctocog alfa - a very long half life factor VIII) where we discuss the evidence.</p><p><br></p><p><strong>HaemSTAR </strong>is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis &amp; thrombosis, transfusion, general haematology, and obstetric haematology.</p>","author_name":"Richard Buka"}